Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others
interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy,
such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
It is not yet known which schedule of rituximab and combination chemotherapy is more
effective in treating non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and
combination chemotherapy to compare how well they work in treating patients with aggressive
B-cell non-Hodgkin's lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
German High-Grade Non-Hodgkin's Lymphoma Study Group